A 32-year-old male agricultural worker from rural Chhattisgarh presents to the primary health centre with fever, chills, and sweating for 3 days. He reports working in paddy fields during the monsoon season. On examination, temperature is 39.5°C, spleen is palpable 2 cm below the costal margin, and liver edge is felt 1 cm below the costal margin. Peripheral blood smear shows ring forms and trophozoites. He is started on chloroquine. After 48 hours, fever persists and parasitaemia increases. Which epidemiological feature of malaria in this region best explains the treatment failure?

Explanation

## Clinical Context The patient is from rural Chhattisgarh (a high malaria endemic zone in central India) with acute malaria and treatment failure on chloroquine. The persistence of parasitaemia and fever despite appropriate dosing indicates drug-resistant parasites. ## Epidemiological Analysis **Key Point:** Chloroquine-resistant *Plasmodium falciparum* (CRPF) is endemic in forested and tribal areas of central India, including Chhattisgarh, Jharkhand, and Odisha. This is the most important epidemiological factor explaining treatment failure in this geographic zone. **High-Yield:** The National Vector Borne Disease Control Programme (NVBDCP) classifies India into malaria endemic zones: - **Zone 1 (High endemic):** Forested tribal areas (Chhattisgarh, Jharkhand, Odisha, parts of Madhya Pradesh) — CRPF is prevalent - **Zone 2 (Low endemic):** Plains and coastal areas — chloroquine-sensitive *P. falciparum* more common - **Zone 3 (Non-endemic):** Himalayan foothills and parts of western India **Clinical Pearl:** In CRPF-endemic areas, treatment failure manifests as: 1. Persistence of fever beyond 48 hours 2. Increasing or persistent parasitaemia on repeat smear 3. Clinical deterioration despite appropriate dosing ## Why CRPF Resistance Occurs Chloroquine resistance in *P. falciparum* is mediated by mutations in the *pfcrt* (chloroquine resistance transporter) gene, which reduces intracellular drug accumulation. This is fixed in populations with prolonged drug pressure. ## Management Implication In CRPF-endemic zones, artemisinin-based combination therapy (ACT) — such as artesunate + amodiaquine or artemether + lumefantrine — is the first-line treatment, not chloroquine [cite:NVBDCP Guidelines 2017]. | Feature | CRPF-Endemic Zone | Chloroquine-Sensitive Zone | | --- | --- | --- | | Geography | Forested tribal areas (Central India) | Plains, coastal regions | | *P. falciparum* prevalence | High (>50% of malaria cases) | Low (<30%) | | Chloroquine efficacy | <50% | >90% | | First-line treatment | ACT (artemisinin-based) | Chloroquine or ACT | | Relapse risk | Low (falciparum does not relapse) | N/A | **Mnemonic:** **CRPF in Forested Tribal Areas (FTA)** — Central India's forested tribal areas have widespread chloroquine-resistant *P. falciparum*.